Chronic Renal Failure (Uremic Phase)
Conditions
Interventions
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Subjects with end-stage renal disease who are eligible for a donation after a first cardiac (or circulatory) donation (DCD) kidney transplant Including but not limited to the following primary kidney diseases: (1) glomerulonephritis; (2) chronic pyelonephritis (reflux nephropathy); (3) hereditary diseases; (4) metabolic diseases; (5) urine Obstructive diseases of the road; (6) Toxic diseases; (7) Systemic diseases; (8) Hemolytic uremic syndrome; (9) Tumors; (10) Congenital malformations; (11) Acute irreversible renal failure, etc.. 2. Male or female subjects (Chinese residents) aged 18-65 years inclusive at the time of screening. 3. Plan to receive ABO blood group-matched heart (or circulating) post-mortem donation (DCD) kidney allograft subjects. 4. Population-reactive antibody (PRA) peak < 10% or the test result is negative. 5. Subjects are able to understand the purpose and risks of the study, are willing and able to participate in the study, and have provided written informed consent to participate in the study and dated. 6. The subject must be a recipient of a DCD kidney transplant, and the organs accepted are only from the Chinese Human Organ Distribution and Sharing System. 7. Subjects agreed not to participate in another interventional study while participating in this study.
Exclusion criteria
Exclusion criteria: 1. The subjects have received or are receiving organ transplantation other than kidney before. 2. Subjects receiving bilateral kidney transplantation. 3. The cold ischemia time of allograft before renal transplantation was more than 24 hours. 4. The researchers believe that the subjects are unlikely to follow the scheduled visit or have a history of non-compliance. 5. Subjects with evidence of active liver disease (liver function test results: alanine aminotransferase [ALT] or aspartate aminotransferase [ast] >= 2 times the upper limit of normal value [ULN]) or with chronic active hepatitis B or hepatitis C within 1 month before kidney transplantation. 6. Active systemic infection requiring antibiotics within one week before renal transplantation. 7. At present, there is a history of malignant tumor (within the past 5 years), except for non metastatic skin basal or squamous cell carcinoma or cervical carcinoma in situ, which has been successfully treated. 8. Subjects who, in the opinion of the investigator, have physical or mental illness and are unable to comply with the requirements of the study. 9. Any disease (including any uncontrolled disease other than end-stage renal disease) considered by the investigator or the sponsor / designee as having inappropriate risk or contraindications for participating in the study, or possibly interfering with the purpose, implementation or evaluation of the study. 10. Female subjects who breast fed or donated eggs at the beginning of the screening period and throughout the study period. One 11. Patients were reluctant to participate in the study. 12. The patient asked to withdraw from the study. 13. In addition to the primary renal diseases, the patients include but are not limited to the following disease states: (1) General scattered malignant tumor; (2) Intractable heart failure; (3) Chronic respiratory failure; (4) Serious vascular disease; (5) Progressive liver disease; (6) Serious systemic infection, active tuberculosis; (7) Coagulation mechanism disorder; (8) Psychosis; (9) AIDS; (10) Drug abuse, etc..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stool sequencing results;Blood metabolome sequencing results;Urine metabolome sequencing results; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological indicators;Interleukin;complement; | — |
Countries
China
Contacts
Public ContactZhou Xiaofeng
China-Japan Friendship Hospital
Outcome results
None listed